The decrease in maternal PlGF levels are evident starting from the beginning of the second trimester in pregnancies with preeclampsia, while higher sFLT1 levels are detected in the third trimester leading to an increased sFLT1:PlGF ratio.30,31 These and more recent data1 prompted the recommendation for clinical PlGF testing to help ruling out preeclampsia in women presenting with clinically suspected disease. The gene discussed is PGF; the disease is preeclampsia.